European Stocks Rebound. AstraZeneca Plunges 9%. Bund Yields Ease From a Two-Month High. Oil Retreats. The Dollar Still Cannot Find a Haven Bid
CAC 40 up 0.6%. DAX up 0.7%. ASML +2.6%, Infineon +3.1%, STMicro +3.7%. FTSE 100 in the red: AstraZeneca down over 9%, its worst day since 2017, after Wainua failed a late-stage cardiac trial. Bund 10Y easing to 3.06% from Wednesday’s two-month high of 3.10%. EUR/USD climbing toward 1.1450 — German trade surplus €19.1B (vs €14.5B prior). GBP/USD at a three-week high above 1.3400. Oil retreating nearly 2% to $73.10. Silver bouncing to $59.12 from Wednesday’s $57.22 low. Crypto holding losses: BTC near $62,300, Fear & Greed at 22.
HIGHEST CONVICTION: Fade the EU 5-year Bund yield rise toward 2.90%. The hawkish ECB repricing looks stretched relative to an oil shock that is potentially reversible if Qatar-mediated diplomacy gains traction.
Two Markets Inside One European Session
Thursday’s European session is a cautious rebound built on a fragile premise: that the Iran situation will de-escalate again, just as it did in June. The Stoxx 600 is up around 0.5%, led by semiconductor names — ASML up 2.6%, Infineon up 3.1%, STMicroelectronics up 3.7% — following strong investor demand for SK Hynix’s US share offering. France’s CAC 40 has recovered around 0.6% of Wednesday’s 2.2% slide. Germany’s DAX is up around 0.7%. The broader rally is happening on reports that Qatar is pressing Tehran to honour the existing memorandum of understanding and contain the escalation.
London is the session’s obvious exception. The FTSE 100 is in the red because AstraZeneca, its second-largest constituent, has plunged more than 9% — its steepest one-day fall since 2017 — after its gene-silencing drug Wainua, developed with Ionis Pharmaceuticals, failed a late-stage trial to prevent cardiac complications. One failed drug trial is erasing more index points than three European chipmakers are recovering.
The entire continental rebound rests on the assumption that Qatar’s mediation succeeds. Trump...